AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ethinyl estradiol (EE2) during childhood (25 ng/kg/d for ages 5-8 years; 50 ng/kg/d for ages >8-12 years)
Number of subjects: 149
Study 24762109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 22386119 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and emotional coping strategies
Number of subjects: 1324
Study 22386119 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal and oppositional coping strategies
Number of subjects: 1324
Study 19515367 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine administration for 5 weeks
Number of subjects: 35
Study 19298040 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated technique
Number of subjects: 84
Study 19298040 — intervention group
Group type: COMPARATOR
Intervention: Nonnavigated technique
Number of subjects: 84
Study 19298040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 15795812 — intervention group
Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 98
Study 15795812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink (CES)
Number of subjects: 98
Study 15795812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink with caffeine (CAF)
Number of subjects: 98
Study 12450644 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone combined with anxiety management training
Number of subjects: 60
Study 12450644 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with anxiety management training
Number of subjects: 60
Study 12450644 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone combined with non-directive therapy
Number of subjects: 60
Study 12450644 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with non-directive therapy
Number of subjects: 60
Study 10908898 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1000 mg/day
Number of subjects: 294
Study 10908898 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 294
Study 10908898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 10908898 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (both dosages combined)
Number of subjects: 294
Study 8769497 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 21
Study 8769497 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Mandibular Positioning (AMP) device
Number of subjects: 21
Study 8769497 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (CPAP and AMP)
Number of subjects: 21
Study 1525702 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DFZ)
Number of subjects: 29
Study 1525702 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PDN)
Number of subjects: 29
Study 3549597 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 3549597 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 30062946 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 2.0 g of TXA orally two hours preoperatively (group A)
Number of subjects: 200
Study 30062946 — intervention group
Group type: COMPARATOR
Intervention: Single dose of TXA followed by 1.0 g orally three hours postoperatively (group B)
Number of subjects: 200
Study 30062946 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C)
Number of subjects: 200
Study 30062946 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D)
Number of subjects: 200
Study 28391391 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching to the point of pain (POP)
Number of subjects: 22
Study 28391391 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching to the point of discomfort (POD)
Number of subjects: 22
Study 26230270 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day desvenlafaxine
Number of subjects: 1562
Study 26230270 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day desvenlafaxine
Number of subjects: 1562
Study 26230270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1562
Study 23023151 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic ureterolithotomy
Number of subjects: 48
Study 23023151 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic ureterolithotomy
Number of subjects: 48
Study 21095914 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (AlGaAs laser, 650 nm, energy density of 2.4 J/cm2)
Number of subjects: 40
Study 21095914 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture (needles)
Number of subjects: 40
Study 18413835 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxercalciferol (10 microg orally, days 1-28) with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Number of subjects: 70
Study 18413835 — intervention group
Group type: COMPARATOR
Intervention: Placebo with docetaxel (35 mg/m2 i.v., days 1, 8, and 15)
Number of subjects: 70
Study 15932141 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 0
Study 15932141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12950597 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'SL 10 g/day
Number of subjects: 65
Study 12950597 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'SL 20 g/day
Number of subjects: 65
Study 12950597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 10475152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (16 children with blunted serum GH peak levels)
Number of subjects: 22
Study 10475152 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (6 subjects with normal serum GH peak values)
Number of subjects: 22
Study 7572258 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MOC; maximum dose 600 mg)
Number of subjects: 56
Study 7572258 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (DOX; maximum dose 250 mg)
Number of subjects: 56
Study 7572258 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (MOC)
Number of subjects: 56
Study 7572258 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (DOX)
Number of subjects: 56
Study 1951126 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 56
Study 1951126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 56
Study 1951126 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 56
Study 1951126 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide or Enalapril (Control Group)
Number of subjects: 56
Study 7036171 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants plus plasma exchanges for one to two months (PE+)
Number of subjects: 14
Study 7036171 — intervention group
Group type: COMPARATOR
Intervention: Pulses of methylprednisolone, immunosuppressive drugs and anticoagulants (Control)
Number of subjects: 14
Study 30549127 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (single oral dose)
Number of subjects: 15
Study 30549127 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (single oral dose)
Number of subjects: 15
Study 30549127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (single oral dose)
Number of subjects: 15
Study 30549127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study 28479493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral SEMS placement
Number of subjects: 133
Study 28479493 — intervention group
Group type: COMPARATOR
Intervention: Unilateral SEMS placement
Number of subjects: 133
Study 26087567 — intervention group
Group type: EXPERIMENTAL
Intervention: Jintian'ge capsule in addition to percutaneous kyphoplasty (PKP)
Number of subjects: 69
Study 26087567 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 69
Study 23579320 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0
Study 23579320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23579320 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (acetaminophen and placebo)
Number of subjects: 0
Study 22384545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI) 20 mL intravenously dripped in 250 mL 0.9% sodium chloride injection from 2-3 days before PCI to 3 days after PCI, once daily.
Number of subjects: 80
Study 22384545 — intervention group
Group type: COMPARATOR
Intervention: Routine medicines including loperamide injection, enteric coated aspirin, Betaloc, and routine rehydration therapy (Control group).
Number of subjects: 80
Study 22384545 — intervention group
Group type: EXPERIMENTAL
Intervention: Danhong Injection (DHI)
Number of subjects: 80
Study 19455042 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at target plasma concentrations (0, 1.3, 1.7, 2.0, 2.4, 2.8 microg ml(‐1))
Number of subjects: 30
Study 16963215 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily cannabis users (N=18)
Number of subjects: 38
Study 16963215 — intervention group
Group type: COMPARATOR
Intervention: Non-daily cannabis users (N=20)
Number of subjects: 38
Study 16963215 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (N=53)
Number of subjects: 38
Study 16963215 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens with detectable cannabinoids
Number of subjects: 38
Study 16963215 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimens screening positive for THC
Number of subjects: 38
Study 15470284 — intervention group
Group type: EXPERIMENTAL
Intervention: Device to guide slow breathing
Number of subjects: 149
Study 15470284 — intervention group
Group type: COMPARATOR
Intervention: Home blood pressure monitoring with simple written instructions
Number of subjects: 149
Study 11168270 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture (CD-group)
Number of subjects: 68
Study 11168270 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-mucosa-borne overdenture on 2 IMZ implants (IMZ-group)
Number of subjects: 68
Study 11168270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainly implant-borne overdenture retained by a transmandibular implant (TMI-group)
Number of subjects: 68
Study 9923572 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASA plain
Number of subjects: 36
Study 9923572 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASA enteric-coated
Number of subjects: 36
Study 9923572 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg ASA plain
Number of subjects: 36
Study 8934981 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg orally 2 hours before sedation)
Number of subjects: 8
Study 8934981 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone (Control group)
Number of subjects: 8
Study 2748718 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycle ergometer exercise sessions and one bronchial hygiene treatment session per day (EX Group)
Number of subjects: 17
Study 2748718 — intervention group
Group type: COMPARATOR
Intervention: Three bronchial hygiene treatment sessions per day (PD Group)
Number of subjects: 17
Study 668102 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 74,917
Number of subjects: 13
Study 668102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30448689 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward Group (competing rewards established by linking CS+ option to high rewards and CS- option to low rewards during acquisition and test)
Number of subjects: 223
Study 30448689 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial-Reward Group (rewards present during acquisition, but discontinued during test)
Number of subjects: 223
Study 30448689 — intervention group
Group type: COMPARATOR
Intervention: No-Reward Group (rewards completely absent)
Number of subjects: 223
Study 26711658 — intervention group
Group type: EXPERIMENTAL
Intervention: Yokukansan (YKS) 7.5 g/day
Number of subjects: 145
Study 26711658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 25897153 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD
Number of subjects: 264
Study 25897153 — intervention group
Group type: COMPARATOR
Intervention: Stanford V
Number of subjects: 264
Study 25453519 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic yoga (16 sessions, twice a week for 8 weeks)
Number of subjects: 47
Study 25453519 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 47
Study 22810441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot randomized study
Number of subjects: 0
Study 22810441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot studies
Number of subjects: 0
Study 18829015 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human FSH plus hCG after GnRH agonist treatment
Number of subjects: 87
Study 18829015 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 87
Study 17697815 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin, clopidogrel, and cilostazol)
Number of subjects: 20
Study 17697815 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (aspirin and clopidogrel)
Number of subjects: 20
Study 15530674 — intervention group
Group type: EXPERIMENTAL
Intervention: HB‐AS04 (2 doses at 0 and 6 months)
Number of subjects: 1303
Study 15530674 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine (3 doses at 0, 1, and 6 months)
Number of subjects: 1303
Study 11586161 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound therapy (20-minute daily applications at the site of the nonunion)
Number of subjects: 29
Study 10558395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster assignment of schools
Number of subjects: 0
Study 10558395 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7924650 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide II (RII) suppository intravaginally, once daily for 50 days
Number of subjects: 0
Study 7924650 — intervention group
Group type: COMPARATOR
Intervention: Placebo, once daily for 50 days
Number of subjects: 0
Study 2476933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordocentesis
Number of subjects: 50
Study 2476933 — intervention group
Group type: COMPARATOR
Intervention: Intravascular transfusion
Number of subjects: 50
Study 2476933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordocentesis with anterior placenta
Number of subjects: 50
Study 2476933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordocentesis with non-anterior placenta
Number of subjects: 50
Study 2476933 — intervention group
Group type: COMPARATOR
Intervention: Cordocentesis vs Intravascular transfusion
Number of subjects: 50
Study 4877801 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized flumedroxone 10 mg t.d.s.
Number of subjects: 0
Study 4877801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31335669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prison-based cognitive behavioral rehabilitation intervention (PCBRI)
Number of subjects: 45
Study 31335669 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 45
Study 28195931 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication adherence
Number of subjects: 35
Study 28195931 — intervention group
Group type: COMPARATOR
Intervention: Poor medication adherence
Number of subjects: 35
Study 25883244 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (20 minutes to motor cortex at 2 mA) for five consecutive days before cognitive behavioural management.
Number of subjects: 135
Study 25883244 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (identical electrode position, stimulator switched off after 30 seconds) for five consecutive days before cognitive behavioural management.
Number of subjects: 135
Study 25883244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural management (four week multidisciplinary programme of 80 hours).
Number of subjects: 135
Study 23088175 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages targeting psychological health
Number of subjects: 96
Study 23088175 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed messages targeting psychological health
Number of subjects: 96
Study 23088175 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 96
Study 23088175 — intervention group
Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 96
Study 21947753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) 50 mg/kg bolus followed by 15 mg/kg/h infusion and another 50 mg/kg into the bypass circuit
Number of subjects: 160
Study 21947753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21947753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 160
Study 18649974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glutamine dipeptide
Number of subjects: 15
Study 18649974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16824141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Number of subjects: 120
Study 16824141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and MMF
Number of subjects: 120
Study 16824141 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (control)
Number of subjects: 120
Study 16824141 — intervention group
Group type: COMPARATOR
Intervention: MMF-free control (Tacrolimus and corticosteroids)
Number of subjects: 120
Study 16824141 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA pharmacokinetics with tacrolimus
Number of subjects: 120
Study 12738555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betaxolol
Number of subjects: 95
Study 12738555 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol
Number of subjects: 95
Study 11270020 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of propofol
Number of subjects: 25
Study 11270020 — intervention group
Group type: COMPARATOR
Intervention: Intermittent boluses of midazolam
Number of subjects: 25
Study 9293933 — intervention group
Group type: EXPERIMENTAL
Intervention: Butyric acid enemas (40 mmol) twice per day for two weeks
Number of subjects: 15
Study 9293933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7994793 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of hydroxypropylcellulose-doxorubicin (20 mg/20 ml)
Number of subjects: 31
Study 7994793 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravesical instillation of hydroxypropylcellulose-doxorubicin and local hyperthermia
Number of subjects: 31
Study 3176836 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 0.5 mg/kg midazolam and 0.05 mg/kg atropine
Number of subjects: 202
Study 3176836 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of 0.15 mg/kg midazolam and 0.02 mg/kg atropine
Number of subjects: 202
Study 31700547 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hallux adduction
Number of subjects: 45
Study 31700547 — intervention group
Group type: COMPARATOR
Intervention: Pre-passive hallux adduction
Number of subjects: 45
Study 28346865 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 20 Hz rTMS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 28346865 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS applied to the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 25490277 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sleep disruption via auditory stimuli
Number of subjects: 14
Study 25490277 — intervention group
Group type: COMPARATOR
Intervention: Normal deep sleep
Number of subjects: 14
Study 24109189 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg + HCTZ 25 mg
Number of subjects: 59
Study 24109189 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol 10 mg + HCTZ 25 mg
Number of subjects: 59
Study 22074958 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine 100 mg simple dose formulation
Number of subjects: 57
Study 22074958 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 57
Study 18202711 — intervention group
Group type: EXPERIMENTAL
Intervention: Oblique injection technique
Number of subjects: 0
Study 18202711 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 0
Study 18202711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study 16442666 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective priming paradigm in the picture‐picture naming task
Number of subjects: 0
Study 16442666 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective priming effects from the naming task
Number of subjects: 0
Study 14606135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 14606135 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) with factor V Leiden mutation
Number of subjects: 0
Study 10678615 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (2,000 microg daily)
Number of subjects: 0
Study 10678615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9076423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipelle (P)
Number of subjects: 365
Study 9076423 — intervention group
Group type: COMPARATOR
Intervention: Cytospat (C)
Number of subjects: 365
Study 9076423 — intervention group
Group type: EXPERIMENTAL
Intervention: D&C
Number of subjects: 365
Study 7687608 — intervention group
Group type: COMPARATOR
Intervention: Histamine challenge (1 mg)
Number of subjects: 8
Study 7687608 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge (increasing doses)
Number of subjects: 8